Soluble IL-2 receptor: A biomarker for assessing myositis activity

Disease Markers

Volumn 2014, Issue , 2014, Pages

  Tournadre, Anne ^a   Dubost, Jean Jacques ^a   Soubrier, Martin ^a   Ruivard, Marc ^b   Souteyrand, Pierre ^b   Schmidt, Jeannot ^a   Clavelou, Pierre ^a   Tridon, Arlette ^c   Ristori, Jean Michel ^a  

^a SERVICE DE RHUMATOLOGIE   (France)

^b UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^c UNIVERSITÉ CLERMONT AUVERGNE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CHLOROQUINE; CREATINE KINASE; CYCLOSPORIN; IMMUNOGLOBULIN; INTERLEUKIN 2 RECEPTOR; METHOTREXATE; PREDNISONE; BIOLOGICAL MARKER;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DERMATOMYOSITIS; DIAGNOSTIC ACCURACY; DISEASE ACTIVITY; DISEASE EXACERBATION; FEMALE; HEPATITIS C; HUMAN; INTERSTITIAL LUNG DISEASE; MALE; MIDDLE AGED; MIXED CONNECTIVE TISSUE DISEASE; MYOSITIS; POLYMYOSITIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; YOUNG ADULT; AGED; BLOOD; CASE CONTROL STUDY; RECEIVER OPERATING CHARACTERISTIC;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOSITIS; RECEPTORS, INTERLEUKIN-2; ROC CURVE; YOUNG ADULT;

EID: 84896936428     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.1155/2014/472624     Document Type: Article

References (17)

1. Hoogendijk J. E., Amato A. A., Lecky B. R., Choy E. H., Lundberg I. E., Rose M. R., Vencovsky J., De Visser M., Hughes R. A., 119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, Naarden, The Netherlands. Neuromuscular Disorders 2004 14 5 337 345 2-s2.0-1942425614 10.1016/j.nmd.2004.02.006
2. Troyanov Y., Targoff I. N., Tremblay J.-L., Goulet J.-R., Raymond Y., Senécal J.-L., Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients. Medicine 2005 84 4 231 249 2-s2.0-22644433770 10.1097/01.md.0000173991.74008.b0
3. Dalakas M. C., Hohlfeld R., Polymyositis and dermatomyositis. The Lancet 2003 362 9388 971 982 2-s2.0-0141651951 10.1016/S0140-6736(03)14368-1
4. Göttfried I., Seeber A., Anegg B., Rieger A., Stingl G., Volc-Platzer B., High dose intravenous immunoglobulin (IVIG) in dermatomyositis: clinical responses and effect on sIL-2R levels. European Journal of Dermatology 2000 10 1 29 35 2-s2.0-0007752117
5. Samsonov M. Y., Nassonov E. L., Tilz G. P., Geht B. M., Demel U., Gurkina G. T., Shtutman V. Z., Guseva A. G., Wachter H., Fuchs D., Elevated serum levels of neopterin in adults patients with polymyositis/dermatomyositis. British Journal of Rheumatology 1997 36 6 656 660 2-s2.0-0346983723
6. Tokano Y., Kanai Y., Hashimoto H., Okumura K., Hirose S., Soluble interleukin 2 receptors in patients with polymyositis/dermatomyositis. Annals of the Rheumatic Diseases 1992 51 6 781 782 2-s2.0-0026703782
7. Wolf R. E., Baethge B. A., Interleukin-1 α interleukin-2, and soluble interleukin-2 receptors in polymyositis. Arthritis and Rheumatism 1990 33 7 1007 1014 2-s2.0-0025282054 10.1002/art.1780330713
8. Kroll M., Otis J., Kagen L., Serum enzyme, myoglobin and muscle strength relationships in polymyositis and dermatomyositis. Journal of Rheumatology 1986 13 2 349 355 2-s2.0-0022888662
9. Oddis C. V., Medsger T. A. Jr., Relationship between serum creatine kinase level and corticosteroid therapy in polymyositis-dermatomyositis. Journal of Rheumatology 1988 15 5 807 811 2-s2.0-0023878645
10. Bohan A., Peter J. B., Polymyositis and dermatomyositis-I. The New England Journal of Medicine 1975 292 7 344 347 2-s2.0-0016850495
11. Griggs R. C., Askanas V., DiMauro S., Engel A., Karpati G., Mendell J. R., Rowland L. P., Inclusion body myositis and myopathies. Annals of Neurology 1995 38 5 705 713 2-s2.0-0028787389 10.1002/ana.410380504
12. Brady S., Squier W., Hilton-Jones D., Clinical assessment determines the diagnosis of inclusion body myositis independently of pathological features. Journal of Neurology, Neurosurgery & Psychiatry 2013 84 1240 1246
13. Tournadre A., Lenief V., Eljaafari A., Miossec P., Immature muscle precursors are a source of interferon- β in myositis: Role of toll-like receptor 3 activation and contribution to HLA class i up-regulation. Arthritis and Rheumatism 2012 64 2 533 541 2-s2.0-84856402922 10.1002/art.33350
14. Tournadre A., Porcherot M., Chérin P., Marie I., Hachulla E., Miossec P., Th1 and Th17 balance in inflammatory myopathies: Interaction with dendritic cells and possible link with response to high-dose immunoglobulins. Cytokine 2009 46 3 297 301 2-s2.0-67349161791 10.1016/j.cyto.2009.02.013
15. Fraser D. D., Frank J. A., Dalakas M., Miller F. W., Hicks J. E., Plotz P., Magnetic resonance imaging in the idiopathic inflammatory myopathies. Journal of Rheumatology 1991 18 11 1693 1700 2-s2.0-0026336021
16. Tomasová S. J., Charvat F., Jarosova K., Vencovsky J., The role of MRI in the assessment of polymyositis and dermatomyositis. Rheumatology 2007 46 7 1174 1179
17. Maillard S. M., Jones R., Owens C., Pilkington C., Woo P., Wedderburn L. R., Murray K. J., Quantitative assessment of MRI T2 relaxation time of thigh muscles in juvenile dermatomyositis. Rheumatology 2004 43 5 603 608 2-s2.0-2442606434 10.1093/rheumatology/keh130